Compare Stocks → The 1,000X Crypto Playbook (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CNCENASDAQ:EVFMNASDAQ:EVLONASDAQ:KALVNASDAQ:MRKR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNCEConcert Pharmaceuticals$8.37$8.37$2.66▼$8.55$401.26M0.522.97 million shsN/AEVFMEvofem Biosciences$0.01-7.8%$0.02$0.01▼$4.36$761K-1.12792,517 shs529,492 shsEVLOEvelo Biosciences$0.04-4.3%$0.05$0.03▼$13.93$835K2.0343,742 shs61,379 shsKALVKalVista Pharmaceuticals$11.75-1.1%$12.91$7.21▼$16.88$495.73M0.88753,431 shs131,598 shsMRKRMarker Therapeutics$4.21-4.3%$4.26$0.76▼$9.68$37.47M1.521,154 shs10,036 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNCEConcert Pharmaceuticals0.00%0.00%0.00%0.00%0.00%EVFMEvofem Biosciences+2.00%-23.50%-18.09%-63.57%-99.55%EVLOEvelo Biosciences+2.22%+9.79%-17.86%-31.34%-98.61%KALVKalVista Pharmaceuticals+1.19%+0.59%-0.42%-8.62%+47.39%MRKRMarker Therapeutics-0.90%-4.97%-0.68%+1.62%+289.38%Crypto Bull Market – Or Crypto Crash on The Horizon? (Ad)Are We Headed for a Historic Crypto Bull Run… OR… Crypto Crash?Click For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AKALVKalVista Pharmaceuticals3.918 of 5 stars3.51.00.04.62.62.50.6MRKRMarker TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNCEConcert PharmaceuticalsN/AN/AN/AN/AEVFMEvofem Biosciences2.00HoldN/AN/AEVLOEvelo Biosciences2.00HoldN/AN/AKALVKalVista Pharmaceuticals3.00Buy$26.33124.11% UpsideMRKRMarker TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest CNCE, EVFM, EVLO, KALV, and MRKR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.002/14/2024KALVKalVista PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$16.00 ➝ $24.002/13/2024KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $35.00(Data available from 4/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNCEConcert Pharmaceuticals$32.58M12.32N/AN/A$3.24 per share2.58EVFMEvofem Biosciences$18.22M0.04$1.41 per share0.01($2.64) per share-0.01EVLOEvelo BiosciencesN/AN/AN/AN/A($0.92) per shareN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/A$4.71 per shareN/AMRKRMarker Therapeutics$3.31M11.32N/AN/A$1.58 per share2.66Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNCEConcert Pharmaceuticals-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/AEVFMEvofem Biosciences$52.98M-$7.62N/A∞N/A290.81%-90.20%331.20%4/26/2024 (Estimated)EVLOEvelo Biosciences-$114.53M-$13.29N/A∞N/AN/AN/A-189.58%5/13/2024 (Estimated)KALVKalVista Pharmaceuticals-$92.91M-$3.15N/AN/AN/AN/A-86.06%-72.65%7/5/2024 (Estimated)MRKRMarker Therapeutics-$8.24MN/A0.00∞N/A-142.62%-39.89%-25.45%5/21/2024 (Estimated)Latest CNCE, EVFM, EVLO, KALV, and MRKR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023EVFMEvofem BiosciencesN/A-$0.44-$0.44-$0.44N/A$4.84 million3/11/2024Q3 2024KALVKalVista Pharmaceuticals-$0.75-$0.84-$0.09-$0.84N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNCEConcert PharmaceuticalsN/A9.039.03EVFMEvofem BiosciencesN/A0.130.10EVLOEvelo BiosciencesN/A0.480.48KALVKalVista PharmaceuticalsN/A5.445.44MRKRMarker TherapeuticsN/A5.575.57OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNCEConcert Pharmaceuticals70.63%EVFMEvofem Biosciences0.22%EVLOEvelo Biosciences0.31%KALVKalVista PharmaceuticalsN/AMRKRMarker Therapeutics22.39%Insider OwnershipCompanyInsider OwnershipCNCEConcert Pharmaceuticals11.33%EVFMEvofem Biosciences0.21%EVLOEvelo Biosciences1.02%KALVKalVista Pharmaceuticals12.30%MRKRMarker Therapeutics24.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCNCEConcert Pharmaceuticals6447.94 million42.51 millionOptionableEVFMEvofem Biosciences3553.96 million53.85 millionNot OptionableEVLOEvelo Biosciences6618.98 million18.79 millionNo DataKALVKalVista Pharmaceuticals11842.19 million37.00 millionOptionableMRKRMarker Therapeutics678.90 million6.76 millionNot OptionableCNCE, EVFM, EVLO, KALV, and MRKR HeadlinesSourceHeadlineVolunteers needed for National Historic Marker Dayromesentinel.com - April 16 at 11:03 AMJennett Marker Named Human Resources Manager For Chore-Timetimesuniononline.com - April 13 at 7:52 AMHaliwa-Saponi Indian Tribe to be featured on Highway Historical Markerwarrenrecord.com - April 11 at 12:59 PMMarker Therapeutics Inc (MRKR)investing.com - April 10 at 8:50 PMWin an overnight stay with afternoon tea at Anantara The Marker Dublin Hotel.irishtimes.com - April 10 at 3:36 AMMicroRNA Liquid Biopsy Test Shows Potential for Early Pancreatic Cancer Detectionprecisionmedicineonline.com - April 9 at 5:13 PMPutnam Marker Honoring Warner Sisters Restored At Foundry Point Parkmsn.com - April 9 at 5:13 PMSite of former Allentown State Hospital to receive Official State Historical Markerwfmz.com - April 9 at 5:13 PMRobert Edgar Sherrill Memorial Marker Will Be Dedicated April 25chattanoogan.com - April 9 at 12:13 PMCinco de Mayo Margarita Battle at The Marker Key West Harbor Resortbocaratonobserver.com - April 9 at 12:13 PMPrincipal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignanciesglobenewswire.com - April 8 at 7:00 AMVolunteers needed April 26 for National Historic Marker Daywestsidenewsny.com - April 7 at 1:24 PMMorrisound Recording Awarded Historical Marker For Contributions To Extreme Metal, Music Industrymetalinjection.net - April 3 at 2:36 PMGlobal Cardiac Marker Testing Market Sees Robust Growth with Rising Incidence of Cardiovascular Diseasesfinance.yahoo.com - April 3 at 2:36 PMMouse Models and Markers for Cerebral Amyloid Angiopathy, ARIAalzforum.org - March 28 at 5:52 PMThe Andy Westcott Band Concert at The Marker Key West Harbor Resortbocaratonobserver.com - March 27 at 9:34 AMMiddle Passage Marker in Port Arthur commemorates ancestors, provides history of local slave tradepanews.com - March 26 at 5:22 AMMarker Therapeutics GAAP EPS of -$1.59, revenue of $3.31Mmsn.com - March 26 at 5:22 AMMarker Therapeutics Reports Year-End 2023 Corporate and Financial Resultsglobenewswire.com - March 25 at 5:45 PMLegends & Lore Marker program accepting grant applicationsthedailynewsonline.com - March 23 at 2:55 AMMarker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conferenceglobenewswire.com - March 22 at 12:30 PMJudge Dismisses Lawsuit Over Removal of Marker Dedicated to Communist Party Leadermsn.com - March 22 at 3:03 AMMarker dedication reset for Temple cemeterytdtnews.com - March 20 at 8:51 PMSpring Break Pool Party with DJ BUGGY at The Markerbocaratonobserver.com - March 19 at 3:40 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsConcert PharmaceuticalsNASDAQ:CNCEConcert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.Evofem BiosciencesNASDAQ:EVFMEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.Evelo BiosciencesNASDAQ:EVLOEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.KalVista PharmaceuticalsNASDAQ:KALVKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.Marker TherapeuticsNASDAQ:MRKRMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401, which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.